Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the prese...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Park, Jin H., Liu, Yingting, Lemmon, Mark A., Radhakrishnan, Ravi
Formato: Artigo
Lenguaje:Inglês
Publicado: Portland Press Ltd. 2012
Materias:
Accelerated Publication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3507260/
https://ncbi.nlm.nih.gov/pubmed/23101586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20121513
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares